Cytokinetics Inc CYTK:NASDAQ

Last Price$46.32Cboe Real-Time Last Sale as of 10:18AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.93(1.97%)
Bid (Size)$46.24 (1)
Ask (Size)$46.42 (100)
Day Low / High$46.22 - 48.31
Volume351.1 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/27/2022

 

Cytokinetics Inc ( NASDAQ )

Price: $46.32
Change: -0.93 (1.97%)
Volume: 351.1 K
10:18AM ET 6/27/2022
 
 

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $59.19
Change: -1.38 (2.28%)
Volume: 45.9 K
10:18AM ET 6/27/2022
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $67.91
Change: -0.25 (0.37%)
Volume: 90.4 K
10:18AM ET 6/27/2022
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $75.25
Change: +0.08 (0.11%)
Volume: 188.6 K
10:17AM ET 6/27/2022
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $117.19
Change: +0.26 (0.22%)
Volume: 12.8 K
10:18AM ET 6/27/2022
 

Read more news Recent News

Cytokinetics Says FDA Advisory Committee to Meet in December to Review NDA for Heart Disease Drug
8:08AM ET 6/24/2022 MT Newswires

Cytokinetics (CYTK) said Friday the US Food and Drug Administration's cardiovascular and renal drugs advisory committee will meet on Dec. 13 to review its...

Insider Sell: Cytokinetics
4:31PM ET 6/17/2022 MT Newswires

Robert I Blum, Director, President & CEO, on June 15, 2022, sold 10,000 shares in Cytokinetics (CYTK) for $394,000. Following the Form 4 filing with the...

Cytokinetics Says Prescription Drug User Fee Act Date for Heart Failure Treatment Application Extended by Three Months
9:29AM ET 6/17/2022 MT Newswires

Cytokinetics (CYTK) said Friday the US Food and Drug Administration has extended the Prescription Drug User Fee Act date for the company's new drug...

Cytokinetics Starts Extension Clinical Study on Drug Candidate for Amyotrophic Lateral Sclerosis
10:05AM ET 6/16/2022 MT Newswires

Cytokinetics (CYTK) said Thursday it has started an open-label extension clinical study to assess the long-term safety and tolerability of reldesemtiv in...

Company Profile

Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
Address350 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.650.624.3000
Number of Employees130
Recent SEC Filing06/24/20228-K
President, Chief Executive Officer & DirectorRobert I. Blum
Vice President-Development OperationsEric Terhaerdt
Chief Financial Officer & Senior Vice PresidentChing W. Jaw
Executive Vice President-Research & DevelopmentFady Ibraham Malik

Company Highlights

Price Open$47.51
Previous Close$47.25
52 Week Range$17.72 - 48.31
Market Capitalization$4.0 B
Shares Outstanding85.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.20
Beta vs. S&P 500N/A
Revenue$31.5 M
Net Profit Margin-396.22%
Return on Equity-164.73%

Analyst Ratings as of 01/31/2022

Buy
11
Overweight
2
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset